Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

Rockville-based biotechnology company Remedy Plan Therapeutics took home $5,000 Thursday as the winner of the Maryland Tech Council's inaugural Bio+Tech18 pitch competition. That money will go toward a larger, $13 million round the company is looking .....»»

Gotham Therapeutics, a Manhattan-based biotech company, has received $54 million in Series A financing to advance research into a novel method of finding oncology drug candidates. The research was... To view the full story, click the title link......»»

Brainstorm Health Daily: October 11, 2018 Good afternoon, readers--This is Sy. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled .....»»

Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion......»»

The city Economic Development Corp. is deploying a $10 million fund to help life sciences companies expand in the city. The first $1 million will go to Quentis Therapeutics, a cancer immunotherapy... To view the full story, click the title link......»»

The city Economic Development Corp. is deploying a $10 million fund to help life sciences companies expand in the city. The first $1 million will go to Quentis Therapeutics, a cancer immunotherapy... To view the full story, click the title link......»»

OncoMed Pharmaceuticals Inc. — whose wide-ranging deals around cancer stem cells once promised to bring in nearly $3 billion — will merge with a London biotech company for $57.4 million, according to terms of the transaction disclosed Wednesday......»»

The deal comes four months after Immune Design Corp. halted its lead cancer vaccine trial and restructured its drug development plans......»»

The deal, which could pay the Peninsula company a $100 million upfront and up to $370 million per target, is the third aimed at assembling CRISPR's components in the body......»»

The 10-year-old company — part of a group of Bay Area companies that have raised billions of dollars over the past decade — recently netted $254 million to develop tests that can sniff out various cancers from a simple blood draw or "liquid biopsy.".....»»

Altschuler said the $54 million in funding "will put rocket boosters under Corner's pioneering work.".....»»

The Watertown startup has an ambitious goal of developing vaccines that provide lifelong protection from cancer and infectious diseases......»»

read more.....»»

The new cell therapy manufacturing facility, which will open early next year, will be able to deliver highly specialized cell therapies to patients in clinical trials at UCSF's women's, children's and cancer hospitals complex across Mariposa Street......»»

Ensign Peak Advisors' GameStop shares ballooned in value from under $900,000 to $8.7 million in the first qua.....»»

Agenus Inc. has signed its largest licensing deal ever for a tumor-fighting antibody that is still in preclinical development......»»

A Durham biotech startup that spun out of Duke University has raised $7 million in seed funding to scale up its purification technology for biotherapeutics. Isolere Bio Inc. announced Wednesday it has raised $7 million in equity from lead inve.....»»

A California firm focused on early detection of cancer picked Research Triangle Park for a $100 million, 400-job project. But that may be just a portion of the overall investment......»»

A gene therapy startup that launched last summer has raised $120 million toward expanding its biotech manufacturing capacity in Grove City. It's the largest Series B financing in Ohio history, according to PitchBook......»»

Rain Therapeutics Inc. was set on Friday to be the fifth Bay Area life science company in eight days to debut on Nasdaq. The Newark cancer therapeutics business raised $125 million in an initial public offering that hit the middle of its price .....»»